Grifols lifts 2023 margin outlook as revenue rises
Reuters
Published May 09, 2023 07:34
Updated May 09, 2023 08:52
BARCELONA (Reuters) -Spanish drugmaker Grifols on Tuesday lifted its 2023 margin outlook after reporting sturdy growth in first-quarter core earnings and revenue as cost-cutting measures took effect and supply of plasma blood used in its medicines recovered.
The company, which was severely hit at the start of the pandemic due to plasma shortages and left its share price three times lower than it was in 2020, has sought to reassure investors with cost-cutting measures and a leadership change.
On Monday Grifols named Executive Chairman Thomas Glanzmann as new chief executive with immediate effect, ending the founding family's executive leadership.
Announcing its results, Grifols said it expects its earnings before interest, taxes, depreciation, and amortisation (EBITDA) to have a margin over its revenue of 22%-24% in 2023, while its previous target was 21%-23%. It said it had already achieved the 21% goal in the first quarter of the year.
It reported a 19% rise in first-quarter EBITDA to 299 million euros ($329.1 million). Its revenue increased by 23% to 1.5 billion euros.
Grifols swung to a net loss of 108 million euros in the first quarter due to its cost-cutting plans.
It now expects to save 50 million euros more than initially planned, to a total of 450 million, due to its strategy to lay off 8.5% of its workforce as it seeks to cut debt.
Its net financial debt stood at 9.3 billion euros in the first quarter of the year, slightly above 2022 levels and equivalent to seven times EBITDA. The company's target is to lower the debt to a ratio of four-to-one by 2024.
($1 = 0.9084 euros)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.